Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3

Quick Thesis

• Rated Sell — the stock prices in success before Phase 3 proof.
• Liquidity is the main support: $326.3M of cash and a 26.8x current ratio.
• The key risk is cash burn: levered free cash flow was -$48.8M TTM.
• Valuation is rich for a pre-revenue biotech: 10,716.0x EV/Revenue.
• I would turn more constructive only if Phase 3 data de-risk pemvidutide and burn narrows.

Executive Summary

Rating: SELL | ALT

I would put my rating as a Sell because Altimmune is still a pre-revenue biotech whose equity value depends on pemvidutide data, not on current operating cash generation. The company does have a meaningful liquidity cushion, with $326.3M of cash and a 26.8x current ratio, but that runway is being consumed by development spending and repeated financing. In my view, the market is already paying for a successful Phase 3 path, while the current numbers still show negative levered free cash flow of -$48.8M TTM and no commercial revenue base. I would move toward a Buy only if Phase 3 data materially de-risk approval and annual free cash burn improves by at least 30M from the current run rate, because that would show the business is moving from funding dependence toward self-funding potential.

Company Profile

Altimmune, Inc. is a late clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland. It is developing pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company has not generated product revenue to date; $41,000 revenue was $41,000, versus $20,000 in 2024, and came from grants and contracts rather than sales. Founded in 2005, it went public under ALT in June 2017 and acquired Spitfire Pharma in July 2019, which brought pemvidutide into the pipeline. It operates in the United States, the United Kingdom, and Australia through Altimmune UK, Ltd. and Altimmune AU Pty, Ltd., and as of December 31, 2025 it had 110.9M shares outstanding, $279.9M of assets, and a $35M Hercules Capital term loan.

Economic Moat

Business Model

The core asset is pemvidutide, and I feel that is the only structural advantage here that could matter over time. Altimmune has moved it through multiple clinical readouts and is now running a Phase 3 trial in MASH while also advancing AUD and ALD studies on the same platform. That matters because the moat is not a broad commercial franchise; it is the combination of a differentiated 1:1 glucagon/GLP-1 mechanism, human data across several liver-disease settings, and a pipeline focus that keeps most research and development dollars behind one program. The Spitfire acquisition in July 2019 matters as well because it brought the lead asset in-house and gave the company control of the program.

The company has also narrowed its portfolio. In 2022, the business was still framed around obesity and liver disease, with pemvidutide and HepTcell as the two main programs; today, HepTcell has been terminated and the company is concentrated on pemvidutide in MASH, AUD, and ALD. I read that as a cleaner strategic focus, but also a more concentrated one: Altimmune has improved the odds that capital is being spent on the best asset, yet the investment case still depends on one program succeeding.

Business & Operating Risks

The biggest disclosed risk is dependence on pemvidutide, because Altimmune has no approved products and no product revenue. According to the risk factors in its SEC 10-K, the company had an accumulated deficit of $649.5M as of December 31, 2025 and a net loss of $88.1M in FY2025, so the business is still consuming capital before any commercial proof exists. The filing also warns that it may be several years, if ever, before a product candidate is ready for commercialization, which means any delay in Phase 3 would push out the entire equity case.

Financing risk is the next pressure point. Altimmune disclosed $273.5M of cash, cash equivalents, restricted cash and short-term investments at year-end 2025, and said that amount is sufficient for at least a twelve-month period but not enough to complete the clinical trials needed for approval or commercialization. The company also flagged that if public float falls below $75.0M, Form S-3 sales are capped at one-third of public float in any 12-month period, which can force a slower or more expensive raise. That is already visible in the financial data: the company is still loss-making and will need external capital before any product revenue arrives.

Clinical failure and data volatility are central as well. The filing says the product candidates are still in development and that interim or preliminary data may materially change as more patient data become available. I do not see that as boilerplate here, because the stock’s value is tied to pemvidutide read-through and there is no commercial base to absorb a setback. A negative or inconclusive Phase 3 result would leave the company with no revenue stream and a large accumulated deficit.

The disclosed risks do not threaten a mature operating moat; they threaten the moat itself, because the company’s only structural advantage is the pemvidutide platform and the filing makes clear that platform is still unproven commercially.

Management Discussion & Analysis

Management is signalling a capital-intensive, multi-program push rather than balance-sheet repair, and it is actively responding to the funding risk by raising capital. Cash and cash equivalents, restricted cash and short-term investments were $273.5M at December 31, 2025, but the company still says it must pursue additional equity or debt financing and monetization of existing programs through partnership arrangements or sales to third parties. The January 27, 2026 registered direct offering brought in net proceeds of about $70.4M, and the April 22, 2026 equity raise added about $211.2M more, which extends runway but also confirms dilution remains part of the model.

The operating mix backs that up. The Hercules Capital term loan was expanded from $100M to $125M, with $15M drawn at closing and $20M drawn at the amendment closing, while the November 2025 at-the-market program allows up to $200M and had $174.2M remaining available at year-end. Research and development expense fell to $66.4M in 2025 from 82.2M in 2024 because IMPACT enrollment was completed and HepTcell was terminated, but management still plans to increase R&D for the foreseeable future as Phase 3 and new indication work scales. That is the right read: the company is not trying to shrink into safety, it is trying to buy time for the clinical platform to work.

In prior filings, management said the Phase 3 obesity program would include four trials, about 5,000 subjects, and three pemvidutide doses, but the 2025 filing pivoted to MASH, AUD, and ALD without any obesity Phase 3 update. I see that as a real strategic reset rather than a continuation of the earlier plan. The tone is more disciplined now, but the funding burden is still front and center.

Recent Events

The most important recent event was the April 22, 2026 equity raise, which closed on April 24 and brought in about $211.2M of net proceeds through common stock, pre-funded warrants, and accompanying warrants. In my view, that strengthens Altimmune’s ability to fund pemvidutide and prepare for the global pivotal Phase 3 MASH trial, but it also weakens per-share economics because the company chose dilution to extend runway rather than finance development from operating cash flow.

The April 16, 2026 annual meeting was also meaningful. Shareholders approved a jump in authorized common stock from 200M to 400M and expanded the 2019 Employee Stock Purchase Plan from 403,500 shares to 1.1M shares. I read that as a clear capital-flexibility move, but it also tells investors the company is preparing for more equity issuance and employee dilution.

The February 2, 2026 annual meeting notice and the March 5, 2026 and May 13, 2026 earnings releases were routine. Recent events therefore strengthen the clinical funding position, but they also confirm that Altimmune’s investment case still rests on repeated capital raises before any Phase 3 readout.

Financial Analysis

Growth

ALT — Financial Growth (Quarterly, USD Mil)

Source: Yahoo Finance — Quarterly Financial Statements

Revenue was flat at $5,000 in Q1 2025, Q2 2025, and Q3 2025, then jumped to $26,000 in Q4 2025 before falling back to $0 in Q1 2026. That Q4 spike looks event-driven rather than a new run rate, so I would not annualize it. EBITDA and net income moved in the same direction but stayed negative throughout, with EBITDA at -$21.5M in Q1 2026 versus -$20.3M in Q1 2025 and diluted EPS improving only to -0.18 from -0.26. The growth signal is bearish because the latest quarter shows no sustained top-line base and the business remains dependent on one-off revenue recognition.

Profitability

ALT — Profitability (TTM)

Source: Yahoo Finance — Trailing Twelve Months (TTM)

TTM operating margin was -318,493.6%, TTM gross margin was -215,138.7%, and TTM EBITDA margin was -318,174.2%, which is the profile of a late clinical-stage biotech that is still carrying essentially no revenue base while funding trials. The huge gap between gross margin and operating margin shows the issue is not cost of goods sold but fixed research and development and overhead costs spread over a tiny revenue base, so I weight the operating and EBITDA lines more heavily than gross margin here. TTM net margin was 0%, while TTM return on assets was -17.2% and TTM return on equity was -28.9%, which means the company is still destroying accounting returns rather than compounding capital. I would watch for operating margin moving toward positive territory and net margin turning positive, because that would signal the business is moving closer to a commercial inflection.

Valuation

ALT — Valuation Multiples

Source: Yahoo Finance

Altimmune is a pre-revenue biotech, so EV/Revenue is the cleanest anchor. The stock trades at 10,716.0x EV/Revenue and 19,640.0x Price/Sales, which means the market is paying for a very large future commercial launch rather than anything in the current income statement. With 9 analyst opinions, the consensus target range of $11 to $28 versus an implied share price of about $5.5, based on $608.8M market cap and 110.9M shares, shows the market is already discounting a much more successful Phase 3 and eventual approval path.

The rest of the stack points the same way. Forward P/E is -4.7x because forward EPS is -$0.7, so earnings are still negative and the multiple is not a useful cheap-or-expensive signal yet. EV/EBITDA is -3.4x for the same reason, since EBITDA remains negative. Price/Book is 1.3x, which is not demanding for a development-stage name, but book value per share is only $2.4, so it offers limited downside support relative to the current price. FCF yield is -8.0%, and levered free cash flow is -$48.8M TTM, or about -$0.4 per share, which tells me the equity is still funding cash burn rather than harvesting it. On the analysis here, I would put fair value in a wide range of roughly $4–$7 per share, which sits below the analyst mean because I weight dilution and negative cash generation more heavily than the consensus appears to. Forward EPS of -$0.7 is also weak relative to peers on a like-for-like basis, because the company is not yet converting its clinical spend into earnings power the way the stronger read-through names are beginning to do. Overall, the valuation picture is a bearish signal.

Leverage

ALT — Leverage & Coverage (Quarterly)

Source: Yahoo Finance — Quarterly Financial Statements

Altimmune’s leverage profile is modest on paper but weak in cash terms. Total Debt/Equity was 7.6%, Current Ratio was 26.8x, and Total Debt was $36M, so the balance sheet has ample near-term liquidity. The problem is cash generation: Operating Cash Flow was -$76.5M TTM and Levered Free Cash Flow was -$48.8M TTM, while Net Debt/EBITDA was 2.9x and FCF Margin was -157,374.6%, which means EBITDA is not converting into cash and the business is still funding itself through the balance sheet. I would call that medium refinancing risk because the current ratio gives room today, but negative operating cash flow and free cash flow will keep eroding the cushion unless clinical progress improves funding access or spending falls. The leverage profile is a bearish signal because liquidity is comfortable now, yet cash burn leaves financial flexibility dependent on continued capital access.

Insider Activity

The insider transaction record I see here is one-sided buying: 9 open-market purchases, 0 open-market sales, and the sample spans just over 3 months, so it is limited but still clear. Buying is broad rather than concentrated, with the CEO and CFO both active alongside other insiders, which points to alignment with shareholders rather than a single isolated signal. I view that as a modest positive, but it does not offset the financing and clinical risks.

Comparable Analysis

Growth

Source: Yahoo Finance

ALT has no reported revenue growth, only $0M of TTM revenue and negative EBITDA of -$98.6M in TTM, while the closest growth comp, RYTM, posted $239.9M of TTM revenue and 46.9% YoY growth. AMLX and GPCR both carried far larger loss bases with EBITDA of -$161.7M and -$265.8M, respectively, so ALT is still a pre-scale balance-sheet and market-value name rather than a commercial growth story. That gap matters because the market is not paying ALT for operating momentum; it is paying for optionality.

Valuation

Source: Yahoo Finance

ALT’s FCF yield of -8.0% is better than SKYE’s -221.3% and GPCR’s -3.4%, but worse than AMLX’s -1.9% and RYTM’s -1.7%, so the cash burn is not the worst in the set but it is still negative. ALT’s EV/Revenue of 10,716.0x and Price/Sales of 19,640.0x are not useful in absolute terms because revenue is only $0M TTM, which means the market is paying for optionality rather than current sales; by contrast, RYTM trades at 32.1x EV/Revenue on $239.9M of revenue, a much cleaner way to underwrite a commercial platform. Forward EPS is also weak at -$0.7 for ALT versus -$0.6 for RYTM, -$1.2 for AMLX, and -$2.1 for GPCR, so ALT is not cheaper on earnings power either. RYTM’s lower leverage and real revenue base help explain why it deserves a much cleaner multiple than ALT, which is still being valued mainly on clinical probability rather than operating proof.

Profitability

Source: Yahoo Finance

Profitability is materially worse than every peer with usable margin data, and the pattern looks structural rather than cyclical. ALT’s gross margin is -215,138.7% and EBITDA margin is -318,174.2% in TTM, while RYTM at least shows 89.0% gross margin despite a -83.2% EBITDA margin, which tells me ALT is not just spending heavily on growth but is also failing at the cost-of-revenue level. ALT’s operating margin of -318,493.6% is far below RYTM’s -68.1%, so this is not simply an opex issue; the business model itself is still far from scale economics. On returns, ALT’s ROE of -28.9% and ROA of -17.2% are better than SKYE’s -233.9% and -95.1%, but worse than AMLX’s -74.7% and -44.1%, GPCR’s -20.2% and -14.9%, and RYTM’s -117.0% and -31.0%, which shows the company is still destroying capital even before commercialization.

Leverage

Source: Yahoo Finance

Leverage is mixed, but the cash position is the one real support. ALT’s total debt/equity is 7.6% and net debt/EBITDA is 2.9x TTM, which is far lighter than RYTM’s 50.5% debt/equity and 1.1x net debt/EBITDA, but ALT’s operating cash flow of -$76.5M TTM and free cash flow of -$48.8M TTM mean the balance sheet is being used to fund losses, not growth. The current ratio of 26.8x and cash of $326.3M, or $1.7 per share, give ALT runway, but they do not make the leverage profile a competitive advantage because the cash is being consumed. In other words, the lower debt load does not translate into a valuation premium the way it would for a profitable peer, because the company still has to prove that the cash can buy a durable clinical outcome.

Conclusion

The tension in Altimmune is simple: the company has enough liquidity to keep pemvidutide moving, but the current valuation already assumes that the next clinical steps work. I would put my rating as a Sell because the numbers still show negative free cash flow of -$48.8M TTM, no product revenue, and a balance sheet that is being used to fund development rather than generate returns.

I would raise my rating more toward a Buy if pemvidutide shows clear Phase 3 de-risking, meaning a data set strong enough to support a materially higher probability of approval and a financing path that does not require repeated equity issuance. In practical terms, I would want to see annual levered free cash flow improve by at least 30M from the current -$48.8M TTM run rate, because that would tell me the company is moving from pure funding dependence toward a more manageable clinical platform. I would also want to see the next update keep the cash runway above the current level without another large raise, since that would reduce dilution pressure and make the per-share math easier to underwrite.

I would move from Sell to Strong Sell if the next clinical update is weak or delayed and the company is forced back to the market before the Phase 3 readout. That would turn the current runway into a dilution overhang with no offsetting commercial revenue, and a raise below the current implied share price would directly reduce per-share value. With no product sales to absorb the hit, the equity would be priced more on financing terms than on science.

Weighing both sides, I think the bear case is more likely to show up first because the company still has to fund development before it can prove commercial value. The clinical asset is real, but until Phase 3 data arrive and cash burn eases, I see more evidence for patience than for conviction, which keeps me at Sell rather than moving to a more constructive rating.

What to Watch Next

• Phase 3 pemvidutide data — clean efficacy would support a move toward Buy.
• Annual levered free cash flow above -$18.8M — would show burn is narrowing.
• Another large equity raise before readout — would increase dilution risk and support a weaker view.
• Cash runway staying above the current level — would reduce near-term financing pressure.
• Delayed or weak clinical update — would support a move toward Strong Sell.

What’s your take? I rated Altimmune (ALT) SELL above — but the goal here is to get this right, not just to publish an opinion. What would you add to this analysis, or which risk or catalyst do you think I’m under- or over-weighting? Tell me in the comments.

Sources

• SEC 10-K Annual Report — filed 2026-03-06
• SEC 8-K Filing (2026-05-13)
• SEC 8-K Filing (2026-04-24)
• SEC 8-K Filing (2026-04-16)
• SEC 8-K Filing (2026-03-05)
• SEC 8-K Filing (2026-02-03)
• SEC 8-K Filing (2026-01-28)
• SEC Form 4 Insider Transaction (2026-05-01)
• SEC Form 4 Insider Transaction (2026-05-01)
• SEC Form 4 Insider Transaction (2026-05-01)
• SEC 10-K Annual Report — FY2026
• SEC 10-K Annual Report — FY2025
• SEC 10-K Annual Report — FY2024
• SEC 10-K Annual Report — FY2023
• SEC 10-K Annual Report — FY2022

Data sourced from Yahoo Finance and SEC EDGAR. Not investment advice.